Germany has announced a new set of health care reforms to close a growing budget gap. At their core, these changes rely on price controls and cost-shifting measures that place increasing pressure on the private sector.
This may look like fiscal discipline. In reality, it reflects a broader pattern that should raise concerns well beyond Europe.
For years, many advanced economies have relied on government price-setting, mandatory rebates, and revenue caps to manage health care spending. These policies keep prices low, but they do so by systematically undervaluing new medicines and limiting the returns innovators can earn. That tradeoff has consequences.
The United States has long taken a different approach. American startups and inventors lead in biotechnology because the system rewards risk-taking, protects intellectual property, and allows successful breakthroughs to earn market-based returns. That environment attracts capital, supports early-stage companies, and sustains a pipeline of new therapies.
Germany’s approach moves in the opposite direction. Policies like clawbacks and enforced price reductions disconnect value from reward. When governments cap revenues or retroactively reclaim earnings, they introduce uncertainty into markets that depend on long-term investment. For large firms, that may mean shifting resources elsewhere. For startups, it can mean never getting funded in the first place.
That distinction matters. More than half of new drugs in the United States come from small companies and startups. These firms operate without steady revenue and rely heavily on venture capital to survive years of research and development. Investors back them because there is a credible path to returns in a market that respects innovation.
When that expectation erodes, so does the willingness to invest.
The effects do not stay contained within one country. Policies that suppress returns in large markets ripple across the global innovation ecosystem. They shift where capital flows, where companies launch, and where scientific breakthroughs ultimately happen.
There is also a broader fairness issue at play. The United States shoulders a disproportionate share of global pharmaceutical research and development. Other wealthy nations benefit from those breakthroughs while contributing less and paying less. Price control regimes reinforce that imbalance by allowing countries to free ride on innovation financed elsewhere.
Germany’s reforms are a reminder of what that model looks like in practice. They may stabilize budgets in the near term, but they do so by leaning further into policies that weaken the incentives driving medical progress.
For U.S. policymakers, the takeaway is straightforward. Importing these kinds of policies would not solve the underlying problem. It would replicate it. Tying American drug prices to those set in price-controlled systems would reduce the returns that fund research, making it harder for startups and innovators to bring new treatments to market.
There are better ways to address global imbalances. Trade tools, stronger enforcement of intellectual property rights, and policies that encourage allied nations to contribute more to research can help spread the burden more evenly without undermining the system that produces innovation.
The stakes go beyond health care budgets. They reach into the future of biotechnology and the broader innovation economy. Preserving an environment that supports invention, investment, and discovery remains essential if the next generation of breakthroughs is going to happen at all.